The effects of coenzyme q10 in acute myocardial infarction
Dr. Srinivasa Jutur, Dr. Sarala Tippannavar
Introduction: Epidemiological reports from the world Health Organization and American Heart Association beginning in the late 1950s required the Presence of at least two or the following for the diagnosis of myocardial infarction: characteristic symptoms, electrocardiographic changes, and a typical rise and fall in biochemical markers. This epidemiological approach was then generally adopted in routine clinical practice, although the rigor with which clinicians apply the electrocardiographic and biochemical criteria for infarction varies considerably.
Methodology: It was randomized placebo-controlled, interventional study. Study was conducted among all clinically and electrocardiographically defined MI patients admitted in Department or Medicine. All clinically defined MI patients were considered. Patients fulfilling the following inclusion criteria were included in the study.
Results: The region-wise distribution of Ml was 69 patients (70.40%) in AMI, 5 patients (5.1%) in global MI and 24(24.48%) in inferior wall MI in CoQ10 and placebo groups (p= 0.541) which was statistically insignificant and comparable among both groups.
Conclusion: CoQJ0 being a naturally occurring biological molecule it can have synergistic effects with fibrinolysis associated myocardial reperfusion injury and its complication.